April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Evaluation of the Retinal Ganglion Cell Complex With Spectral-Domain (Fourier-Domain) OCT in Patients Undergoing Anti-VEGF Therapy With Ranibizumab and Bevacizumab for Exudative Age-Related Macular Degeneration
Author Affiliations & Notes
  • N. J. Mehta
    Colorado Retina Center, Denver, Colorado
  • H. Quiroz-Mercado
    Denver Health Medical Center, University of Colorado, Denver, Colorado
  • A. M. Pinero-Rodriguez
    Clinica Pinero, Sevilla, Spain
  • J. M. Jimenez-Sierra
    Clinica Oftalmologica Anzures, Mexico City, Mexico
  • L. Lopez-Ramos
    Clinica Oftalmologica Anzures, Mexico City, Mexico
  • Footnotes
    Commercial Relationships  N.J. Mehta, Optovue, C; Optovue, R; H. Quiroz-Mercado, None; A.M. Pinero-Rodriguez, None; J.M. Jimenez-Sierra, None; L. Lopez-Ramos, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4933. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. J. Mehta, H. Quiroz-Mercado, A. M. Pinero-Rodriguez, J. M. Jimenez-Sierra, L. Lopez-Ramos; Evaluation of the Retinal Ganglion Cell Complex With Spectral-Domain (Fourier-Domain) OCT in Patients Undergoing Anti-VEGF Therapy With Ranibizumab and Bevacizumab for Exudative Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4933.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine how the retinal ganglion cell complex (GCC), composed of the inner retinal layers, is affected by pan-VEGF inhibition in patients undergoing treatment for exudative age-related macular degeneration (AMD).

Methods: : 13 eyes from 11 patients diagnosed with AMD and choroidal neovascularization (CNV) from 2007-2009, with visual acuities between 20/25 and 20/400, were enrolled, along with 4 control eyes (untreated contralateral eyes with dry AMD); none of the patients had glaucoma. All patients with CNV were treated with between 2 and 13 intravitreal injections of either ranibizumab or bevacizumab.Patients were imaged with Fourier-domain (FD) OCT both before receiving treatment and on the most recent follow-up. GCC thickness was measured in 8 sectors surrounding the fovea and extending out to 5 mm; the central 2 mm fovea was not analyzed because there are no ganglion cells in the foveola.

Results: : There was an average decrease of 17.2 microns in pre-treatment vs. post-treatment GCC thickness, averaged across all sectors. There was a slight increase in GCC thickness of 2.2 microns on average for the control group. Follow-up averaged 8.4 months in the treated group and 6.5 months in the control group. The treated group received on average 5.8 injections over the course of the follow-up. There was a significant correlation between the number of injections and the amount of GCC thinning (r=0.50; p<0.05). We also compared the GCC thickness both pre-and post treatment against the FD-OCT normative database. In the treatment group there were 25 sectors (24.0%) that were below normal limits (p <0.05) before treatment, and 61 sectors (59.0%) below normal limits (p<0.05) after treatment. In the control group, there were 5 sectors (15.6%) below normal (p<0.05) on the first visit, and 3 sectors (9.4%) below normal (p<0.05) on the last visit.

Conclusions: : The present study demonstrates that pan-VEGF AMD treatment may lead to GCC thinning. These results are consistent with previous animal studies demonstrating possible VEGF dependence of the GCC. The effect on visual function is unknown. Limitations of this study include a small sample size, and limited follow-up in some cases. Additional studies with larger sample sizes and longer follow-up are necessary to validate these findings.

Keywords: age-related macular degeneration • retina: proximal (bipolar, amacrine, and ganglion cells) • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.